Nasdaq Issues Immediate Delisting Notice for Common Stock and Warrants Due to Bid Price Deficiency and Prior Reverse Split
SXTP has more than doubled off its 52-week low of $1.36.
Summary
60 Degrees Pharmaceuticals received an immediate delisting notice from Nasdaq for failing to meet the minimum bid price requirement, exacerbated by a prior reverse stock split that disqualifies it from a compliance period.
Key Events · Corporate Governance and Compliance · SXTP
-
Received Nasdaq Delisting Notice
On January 20, 2026, the company received a notice from Nasdaq indicating a determination to delist its common stock and warrants from The Nasdaq Capital Market.
-
Failed Minimum Bid Price Rule
Nasdaq staff determined the common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
-
Immediate Delisting Due to Prior Reverse Split
The company is not eligible for a compliance period under Nasdaq Listing Rule 5810(c)(3)(A)(iv) because it effected a 1-for-5 reverse stock split on February 24, 2025, leading to immediate delisting.
-
Warrants Also Subject to Delisting
The company's warrants (SXTPW) are also subject to delisting under Nasdaq Listing Rule 5560(a) as the underlying common stock will no longer be listed.
Analysis · SXTP · Life Sciences
60 Degrees Pharmaceuticals, Inc. faces an immediate delisting from Nasdaq, a critical event for a micro-cap company. The delisting notice stems from the company's failure to maintain the minimum $1.00 bid price. Crucially, Nasdaq denied a compliance period due to a prior 1-for-5 reverse stock split in February 2025, making the delisting effective immediately. While the company has appealed the decision, there is no guarantee of a favorable outcome, creating significant uncertainty for investors. This event severely impacts the company's ability to access capital markets and maintain investor confidence, especially following a recent 1-for-4 reverse stock split on January 20, 2026, which was likely an attempt to regain compliance.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 42% of the 479 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.44%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SXTP was trading at $4.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1M. The 52-week trading range was $1.36 to $24.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.